Cell coding company bit.bio has launched a new disease model cell offering enabling scientists to commission disease-relevant mutation of interest. The company’s new Custom ioDisease Model Cells offering lets scientists choose the disease-relevant mutation they’re interested in. The disease-relevant mutation is engineered into bit.bio’s human ioWild Type cells using CRISPR/Cas9 gene editing. As disease model cells come […]
